These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12452297)

  • 1. Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment.
    Thomas AR; Cieslak PR; Strausbaugh LJ; Fleming DW
    Infect Control Hosp Epidemiol; 2002 Nov; 23(11):683-8. PubMed ID: 12452297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin in Oregon: who's using it and why.
    Cieslak PR; Strausbaugh LJ; Fleming DW; Ling JM
    Infect Control Hosp Epidemiol; 1999 Aug; 20(8):557-60. PubMed ID: 10466557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium.
    Belliveau PP; Rothman AL; Maday CE
    Am J Health Syst Pharm; 1996 Jul; 53(13):1570-5. PubMed ID: 8809278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium.
    Anglim AM; Klym B; Byers KE; Scheld WM; Farr BM
    Arch Intern Med; 1997 May; 157(10):1132-6. PubMed ID: 9164379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vancomycin resistant Enterococci (VRE)].
    Lesens O
    Nephrol Ther; 2009 Jun; 5 Suppl 4():S261-4. PubMed ID: 19596346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin use in a university medical center: effect of a vancomycin continuation form.
    Evans ME; Millheim ET; Rapp RP
    Infect Control Hosp Epidemiol; 1999 Jun; 20(6):417-20. PubMed ID: 10395144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interventional program to improve antibiotic use.
    Feucht CL; Rice LB
    Ann Pharmacother; 2003 May; 37(5):646-51. PubMed ID: 12708938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. For nosocomial vancomycin-resistant enterococcal infections: the ounce of prevention or the pound of cure?
    Farr BM
    Clin Infect Dis; 2004 Apr; 38(8):1116-8. PubMed ID: 15095216
    [No Abstract]   [Full Text] [Related]  

  • 9. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Hospital Infection Control Practice Advisory Committee.
    Salemi C; Becker L; Morrissey R; Warmington J
    Clin Perform Qual Health Care; 1998; 6(1):12-6. PubMed ID: 10177043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in vancomycin utilization in adults in a Saudi Arabian Medical Center using the Hospital Infection Control Practices Advisory Committee guidelines and simple educational activity.
    Dib JG; Al-Tawfiq JA; Al Abdulmohsin S; Mohammed K; Jenden PD
    J Infect Public Health; 2009; 2(3):141-6. PubMed ID: 20701874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus.
    Morgan AS; Brennan PJ; Fishman NO
    Ann Pharmacother; 1997 Sep; 31(9):970-3. PubMed ID: 9296233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term control of vancomycin-resistant Enterococcus faecium at the scale of a large multihospital institution: a seven-year experience.
    Fournier S; Brossier F; Fortineau N; Gillaizeau F; Akpabie A; Aubry A; Barbut F; Chedhomme FX; Kassis-Chikhani N; Lucet JC; Robert J; Seytre D; Simon I; Vanjak D; Zahar JR; Brun-Buisson C; Jarlier V
    Euro Surveill; 2012 Jul; 17(30):. PubMed ID: 22856512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin-resistant enterococci.
    Rubinstein E; Keynan Y
    Crit Care Clin; 2013 Oct; 29(4):841-52. PubMed ID: 24094380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals.
    Fridkin SK; Edwards JR; Pichette SC; Pryor ER; McGowan JE; Tenover FC; Culver DH; Gaynes RP
    Clin Infect Dis; 1999 May; 28(5):1119-25. PubMed ID: 10452645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a vancomycin restriction policy in changing the prescribing patterns of house staff.
    Richardson LP; Wiseman SW; Malani PN; Lyons MJ; Kauffman CA
    Microb Drug Resist; 2000; 6(4):327-30. PubMed ID: 11272262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin use in 2 Ontario tertiary care hospitals: a survey.
    Kwan T; Lin F; Ngai B; Loeb M
    Clin Invest Med; 1999 Dec; 22(6):256-64. PubMed ID: 10664867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting.
    Montecalvo MA; Jarvis WR; Uman J; Shay DK; Petrullo C; Horowitz HW; Wormser GP
    Infect Control Hosp Epidemiol; 2001 Jul; 22(7):437-42. PubMed ID: 11583213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines.
    Evans ME; Kortas KJ
    Infect Control Hosp Epidemiol; 1996 Jun; 17(6):356-9. PubMed ID: 8805065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interventions implemented to control an outbreak of vancomycin-resistant enterococci in a university hospital].
    Henard S; Cao-Huu T; Loos-Ayav C; Chanet P; Kessler M; Rabaud C
    Nephrol Ther; 2009 Jun; 5 Suppl 4():S265-71. PubMed ID: 19596347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDC VRE guidelines still relevant.
    Hosp Peer Rev; 1998 Feb; 23(2):25-7. PubMed ID: 10178213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.